Evidence map›Paper›PMID 27811057›Full record

ArticleThe Journal of experimental medicine2016

Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.

Sylvain Delaunay, Francesca Rapino, Lars Tharun, Zhaoli Zhou, Lukas Heukamp, Martin Termathe, Kateryna Shostak, Iva Klevernic, Alexandra Florin, Hadrien Desmecht and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 178 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Sylvain DelaunayLaboratory of Cancer Signaling, University of Liège, 4000 Liège, Belgium.ORCID 0000-0002-8459-6432
Francesca RapinoLaboratory of Cancer Signaling, University of Liège, 4000 Liège, Belgium.
Lars TharunInstitute for Pathology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0001-7375-0775
Zhaoli ZhouLaboratory of Cancer Signaling, University of Liège, 4000 Liège, Belgium.ORCID 0000-0003-4217-2567
Lukas HeukampInstitute for Pathology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0002-3388-3482
Martin TermatheMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, 48149 Muenster.ORCID 0000-0002-5618-4633
Kateryna ShostakLaboratory of Medical Chemistry, University of Liège, 4000 Liège, Belgium.
Iva KlevernicLaboratory of Medical Chemistry, University of Liège, 4000 Liège, Belgium.ORCID 0000-0003-0919-166X
Alexandra FlorinInstitute for Pathology, University Hospital Cologne, 50937 Cologne, Germany.ORCID 0000-0002-2330-4176
Hadrien DesmechtLaboratory of Medical Chemistry, University of Liège, 4000 Liège, Belgium.
Christophe J DesmetGIGA-Infection, Immunity and Inflammation, University of Liège, 4000 Liège, Belgium.ORCID 0000-0002-5723-2449
Laurent NguyenGIGA-Neurosiences, University of Liège, 4000 Liège, Belgium.
Sebastian A LeidelMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, 48149 Muenster.ORCID 0000-0002-0523-6325
Anne E WillisMedical Research Council Toxicology Unit, Leicester LE1 9HN, England, UK.
Reinhard BüttnerInstitute for Pathology, University Hospital Cologne, 50937 Cologne, Germany.
Alain ChariotLaboratory of Medical Chemistry, University of Liège, 4000 Liège, Belgium Alain.Chariot@ulg.ac.be Pierre.Close@ulg.ac.be.ORCID 0000-0002-1691-4347
Pierre CloseLaboratory of Cancer Signaling, University of Liège, 4000 Liège, Belgium Alain.Chariot@ulg.ac.be Pierre.Close@ulg.ac.be.ORCID 0000-0002-8844-9616
University of Liège · BEUniversity Hospital Cologne · DEUniversity of Münster · DEMedical Research Council · GB

Funding

Medical Research Council MC_UP_A600_1023
6 · The paper itself

Abstract

Quantitative and qualitative changes in mRNA translation occur in tumor cells and support cancer progression and metastasis. Posttranscriptional modifications of transfer RNAs (tRNAs) at the wobble uridine 34 (U34) base are highly conserved and contribute to translation fidelity. Here, we show that ELP3 and CTU1/2, partner enzymes in U34 mcm

Indexed as

Protein BiosynthesisAnimalsBreast NeoplasmsCell MovementChromosomal Proteins, Non-HistoneFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHistone AcetyltransferasesHumansInternal Ribosome Entry SitesLymphoid Enhancer-Binding Factor 1MCF-7 CellsMiceModels, BiologicalNeoplasm Invasiveness5-carbomethoxymethyl-2-thiouridineChromosomal Proteins, Non-HistoneDEK protein, humanELP3 protein, humanHistone AcetyltransferasesInternal Ribosome Entry SitesLymphoid Enhancer-Binding Factor 1Nerve Tissue ProteinsOncogene ProteinsPoly-ADP-Ribose Binding ProteinsRNA, TransferThiouridine

Identifiers

PMID27811057
PMCPMC5068235
OpenAlexW2530933900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.